Luke Whitesell

Author PubWeight™ 59.37‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell 2007 8.84
2 HSF1 drives a transcriptional program distinct from heat shock to support highly malignant human cancers. Cell 2012 2.94
3 Tight coordination of protein translation and HSF1 activation supports the anabolic malignant state. Science 2013 2.79
4 17AAG: low target binding affinity and potent cell activity--finding an explanation. Mol Cancer Ther 2003 2.74
5 Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc Natl Acad Sci U S A 2009 2.35
6 Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol Cancer Ther 2004 2.16
7 High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer. Proc Natl Acad Sci U S A 2011 2.03
8 Fitness trade-offs restrict the evolution of resistance to amphotericin B. PLoS Biol 2013 1.88
9 Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. Clin Cancer Res 2007 1.80
10 Hsp90: an emerging target for breast cancer therapy. Anticancer Drugs 2004 1.64
11 A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study. Clin Cancer Res 2007 1.61
12 Actin microfilament aggregation induced by withaferin A is mediated by annexin II. Nat Chem Biol 2005 1.55
13 Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells. Nat Biotechnol 2013 1.33
14 Using the heat-shock response to discover anticancer compounds that target protein homeostasis. ACS Chem Biol 2011 1.31
15 Loss of tumor suppressor NF1 activates HSF1 to promote carcinogenesis. J Clin Invest 2012 1.25
16 Search for Hsp90 inhibitors with potential anticancer activity: isolation and SAR studies of radicicol and monocillin I from two plant-associated fungi of the Sonoran desert. J Nat Prod 2006 1.20
17 Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors. Clin Cancer Res 2003 1.12
18 2,3-Dihydrowithaferin A-3beta-O-sulfate, a new potential prodrug of withaferin A from aeroponically grown Withania somnifera. Bioorg Med Chem 2008 1.12
19 A rhizosphere fungus enhances Arabidopsis thermotolerance through production of an HSP90 inhibitor. Plant Physiol 2007 1.11
20 Heat shock protein 90: a unique chemotherapeutic target. Semin Oncol 2006 1.06
21 Hsp90 is essential in the filarial nematode Brugia pahangi. Int J Parasitol 2005 1.05
22 Cytotoxic constituents of Aspergillus terreus from the rhizosphere of Opuntia versicolor of the Sonoran Desert. J Nat Prod 2003 1.01
23 Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin. Int J Cancer 2005 1.00
24 Ponicidin and oridonin are responsible for the antiangiogenic activity of Rabdosia rubescens, a constituent of the herbal supplement PC SPES. J Nat Prod 2004 0.99
25 Two cases of pediatric neuroblastoma with tumor thrombus in the inferior vena cava. J Pediatr Hematol Oncol 2002 0.98
26 Inhibiting GPI anchor biosynthesis in fungi stresses the endoplasmic reticulum and enhances immunogenicity. ACS Chem Biol 2012 0.98
27 Geopyxins A-E, ent-kaurane diterpenoids from endolichenic fungal strains Geopyxis aff. majalis and Geopyxis sp. AZ0066: structure-activity relationships of geopyxins and their analogues. J Nat Prod 2012 0.96
28 Expression of a unique drug-resistant Hsp90 ortholog by the nematode Caenorhabditis elegans. Cell Stress Chaperones 2003 0.92
29 HSP90: a rising star on the horizon of anticancer targets. Future Oncol 2005 0.92
30 The anticancer activity of the fungal metabolite terrecyclic acid A is associated with modulation of multiple cellular stress response pathways. Mol Cancer Ther 2005 0.91
31 Isolation, optimization of production and structure-activity relationship studies of monocillin I, the cytotoxic constituent of Paraphaeosphaeria quadriseptata. J Antibiot (Tokyo) 2004 0.90
32 Structure-activity relationships for withanolides as inducers of the cellular heat-shock response. J Med Chem 2014 0.88
33 Piperazinyl quinolines as chemosensitizers to increase fluconazole susceptibility of Candida albicans clinical isolates. Bioorg Med Chem Lett 2011 0.87
34 A new dihydroxanthenone from a plant-associated strain of the fungus Chaetomium globosum demonstrates anticancer activity. Bioorg Med Chem 2006 0.87
35 Autoantibodies to villin occur frequently in IPEX, a severe immune dysregulation, syndrome caused by mutation of FOXP3. Clin Immunol 2011 0.87
36 Overcoming fluconazole resistance in Candida albicans clinical isolates with tetracyclic indoles. Bioorg Med Chem Lett 2012 0.85
37 Evidence for a Novel, Caspase-8-Independent, Fas Death Domain-Mediated Apoptotic Pathway. J Biomed Biotechnol 2004 0.81
38 Biomimetic kinetic resolution: highly enantio- and diastereoselective transfer hydrogenation of aglain ketones to access flavagline natural products. J Am Chem Soc 2014 0.81
39 ML212: A small-molecule probe for investigating fluconazole resistance mechanisms in Candida albicans. Beilstein J Org Chem 2013 0.81
40 Design of quinolinedione-based geldanamycin analogues. Bioorg Med Chem Lett 2003 0.76
41 Synthesis and biological evaluation of novobiocin analogues as potential heat shock protein 90 inhibitors. Bioorg Med Chem 2013 0.76
42 Preface. Adv Cancer Res 2016 0.75